12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

R3421: Phase II started

BioCryst began a 2-part, double-blind, placebo-controlled, dose-ranging, U.S. Phase II trial to evaluate oral BCX-4208 in up to 120 patients. The first portion will evaluate 40, 80...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >